Age-related Macular Degeneration (AMD) Market Share, Size, Trends, Industry Analysis Report, By Drugs (Lucentis, Eylea, Avastin, Others); By Product; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2022 - 2030

Report Summary

The global Age-related Macular Degeneration (AMD) Market was valued at USD 7.47 billion in 2021 and is expected to grow at a CAGR of 7.9% during the forecast period. Rising Research and Development (R&D) investments, as well as increased approvals for new medications, are important drivers of Age-related Macular Degeneration (AMD) market expansion.

Know more about this report: Request for sample pages

For instance, in October 2021, Roche has announced the approval of Susvimo (ranibizumab injection) 100 mg/mL by the US Food and Drug Administration (FDA) of intravenous injection use through an ocular augmentation in people with age-related macular degeneration (AMD) who have earlier received two of the anti-vascular endothelial growth factor (VEGF) infusions.

Also, the United States Food and Drug Administration (FDA) granted GT005; an experimental, one-time AAV gene therapy received fast-track designation in September 2020. Gyroscope Therapeutics Limited has developed GT005, which is a one-time experimental gene treatment for GA owing to AMD that is given under the retina and is based on AAV2.

Industry Dynamics

Growth Drivers
The global burden of AMD continues to rise at an unprecedented speed as the global population grows and the demographics reflect a majority of older people. AMD is a primary cause of visual loss in the elderly, according to the National Eye Institute. Furthermore, those over the age of 60 are at a higher risk of having the condition.

AMD is predicted to become more common as the world's population ages, with a higher frequency in Western countries. According to the Globe Health Organization, there are currently around 1.1 billion tobacco users in the world, with that figure likely to double by 2050 if current trends continue. As a result, cigarette use is thought to be a major contributor to the global increase in AMD prevalence.

Furthermore, as the global population of people aged 60 and up grows, so does the prevalence of AMD. According to the United Nations' Globe Population Prospects report, there were around 962 million individuals aged 60 and more in the world in 2017, with the number predicted to more than double by 2050.

According to WHO, myopia and high myopia were expected to affect around 52.0% and 10.0% of the global population, respectively, by 2050. The prevalence of myopia is high in East Asia, where China, Japan, the Republic of Korea, and Singapore.

Report Segmentation

The market is primarily segmented based on product, drugs, route of administration, distribution channel, and region.

Know more about this report: Request for sample pages

Insight by Product

Based on the product segment, the wet AMD segment is expected to be the most significant revenue contributor in the global Age-related Macular Degeneration (AMD) market. Wet age-related macular degeneration is the start of normal blood vessel growth beneath the retina. The expanding geriatric population around the world is producing a high-level demand in the wet age-related macular degeneration market since AMD is the most prevalent cause of significant loss of vision in those over 50 years of age.

According to the United Nations World Ageing 2019 report, East and Southeast Asia are predicted to see the biggest increase of about 312 million people in the next years. Furthermore, in North America and Europe, approximately 200 million people aged 65 and up lived in 2019. The figures above show that there will be a strong demand for solutions to treat wet age-related macular degeneration in the future all across the world.

Geographic Overview

North America had the largest revenue share in the global market. The rising incidence of the geriatric population and age-related macular degeneration, the participation of important market players, and increased research and development activities are some of the forces influencing Age-related Macular Degeneration (AMD) market expansion in the North American area. Furthermore, the American Macular Degeneration Foundation (AMDF) in the United States disseminated this information to warn AMD patients and eye care professionals about the potential danger.

Around the world, advanced AMD is a primary cause of permanent blindness and visual impairment. As a result, the market is growing as AMD's load grows. Further, Wet age-related macular degeneration is one of the leading causes of visual loss in adults over 65, according to the Canadian Ophthalmological Society.

One of its studies, released in 2019, predicted that by 2032, at least one out of every four Canadians would have age-related macular degeneration. As a result of the aforementioned factors, the market in the region is predicted to develop significantly over the forecast period.

Moreover, Asia Pacific is expected to witness a high CAGR in the global Age-related Macular Degeneration (AMD) market. The sale of medications for exudative AMD in APAC is currently insignificant due to a lack of accessibility and expensive drug costs. The region, however, has a high prevalence of AMD, making it a potentially growing market.

Furthermore, in APAC, the presence of companies involved in the marketing and research of exudative AMD medicines is fairly low. In addition, the region accounts for more than a third of all age-related macular degeneration cases recorded globally therefore demand for wet age-related macular degeneration medications is projected to increase dramatically in the future years.

Competitive Insight

Some of the major players operating in the global market include Acucela Inc., Alimera Sciences Inc., ALLERGAN, Bausch & Lomb Incorporated, Bayer AG, F. Hoffmann La Roche, GlaxoSmithKline PLC, Novartis AG, Ophthotech Corporation, Pfizer Inc, Regeneron Pharmaceuticals, Rxi Pharmaceuticals Inc., Santen Pharmaceuticals Co., and Valeant Pharmaceuticals International, Inc. among others.

Age-related Macular Degeneration (AMD) Market Report Scope